See more : Lescarden Inc. (LCAR) Income Statement Analysis – Financial Results
Complete financial analysis of Global Cord Blood Corporation (CO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Global Cord Blood Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Emerging World Pharma, Inc. (EWPI) Income Statement Analysis – Financial Results
- Beijing Bewinner Communications Co., Ltd. (002148.SZ) Income Statement Analysis – Financial Results
- Third Harmonic Bio, Inc. (THRD) Income Statement Analysis – Financial Results
- Happiest Minds Technologies Limited (HAPPSTMNDS.NS) Income Statement Analysis – Financial Results
- Cielo S.A. (CIEL3.SA) Income Statement Analysis – Financial Results
Global Cord Blood Corporation (CO)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.globalcordbloodcorp.com
About Global Cord Blood Corporation
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.24B | 1.16B | 1.22B | 986.75M | 936.77M | 759.98M | 663.00M | 635.12M | 572.86M | 526.12M | 380.49M | 339.53M | 261.54M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 183.31M | 178.95M | 189.13M | 186.03M | 181.48M | 142.64M | 144.60M | 130.61M | 106.23M | 106.62M | 86.66M | 77.38M | 65.73M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.06B | 980.69M | 1.03B | 800.73M | 755.29M | 617.34M | 518.40M | 504.51M | 466.63M | 419.50M | 293.83M | 262.16M | 195.81M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 85.26% | 84.57% | 84.52% | 81.15% | 80.63% | 81.23% | 78.19% | 79.44% | 81.46% | 79.73% | 77.22% | 77.21% | 74.87% | 0.00% | 0.00% | 0.00% |
| Research & Development | 22.30M | 23.77M | 21.11M | 14.69M | 12.72M | 10.37M | 8.96M | 9.91M | 9.77M | 8.46M | 7.62M | 6.96M | 5.82M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 187.06M | 174.36M | 190.23M | 169.32M | 243.50M | 189.94M | 169.95M | 131.68M | 112.24M | 108.05M | 89.70M | 83.79M | 53.32M | 11.20M | 0.00 | 0.00 |
| Selling & Marketing | 241.73M | 237.69M | 261.96M | 235.06M | 219.20M | 178.48M | 148.16M | 127.93M | 112.69M | 93.68M | 61.68M | 47.58M | 39.48M | 0.00 | 0.00 | 0.00 |
| SG&A | 428.79M | 412.05M | 452.19M | 404.38M | 462.70M | 368.42M | 318.11M | 259.61M | 224.93M | 201.73M | 151.37M | 131.38M | 92.80M | 11.20M | 4.01M | 66.28K |
| Other Expenses | 6.27M | 8.16M | 7.39M | 5.70M | 4.23M | 5.97M | -113.00K | 861.00K | 2.21M | 203.00K | 0.00 | 0.00 | 0.00 | 594.98K | 220.52K | 166.41K |
| Operating Expenses | 451.08M | 435.82M | 473.30M | 419.07M | 475.42M | 352.47M | 327.07M | 269.52M | 234.71M | 210.19M | 158.99M | 138.34M | 98.61M | 11.80M | 4.23M | 232.69K |
| Cost & Expenses | 634.39M | 614.77M | 662.43M | 605.10M | 656.91M | 495.11M | 471.67M | 400.13M | 340.93M | 316.81M | 245.65M | 215.71M | 164.34M | 11.80M | 4.23M | 232.69K |
| Interest Income | 32.61M | 30.90M | 25.36M | 25.32M | 21.94M | 17.42M | 18.22M | 18.25M | 16.87M | 15.06M | 13.43M | 9.07M | 6.41M | 4.11M | 0.00 | 250.79K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 3.26M | 119.42M | 107.97M | 101.10M | 70.08M | 70.10M | 3.29M | 2.61M | 2.43M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 19.91M | -26.82M | 12.97M | 52.37M | 50.59M | 50.48M | 50.17M | 50.61M | 37.07M | 35.87M | 29.36M | 23.48M | 20.43M | 3.92M | 7.10M | 250.79K |
| EBITDA | 628.78M | 518.05M | 572.00M | 404.75M | 353.60M | 333.71M | 299.10M | 306.33M | 297.44M | 256.96M | 174.26M | 151.71M | 96.81M | -7.88M | 2.87M | 18.11K |
| EBITDA Ratio | 50.58% | 44.67% | 46.83% | 41.02% | 37.75% | 43.91% | 45.11% | 48.23% | 51.92% | 48.84% | 45.80% | 44.68% | 37.02% | 0.00% | 0.00% | 0.00% |
| Operating Income | 608.87M | 544.87M | 559.03M | 381.66M | 279.86M | 264.87M | 191.33M | 235.00M | 231.93M | 209.31M | 134.84M | 123.82M | 97.19M | -11.80M | -4.23M | -232.69K |
| Operating Income Ratio | 48.97% | 46.99% | 45.77% | 38.68% | 29.88% | 34.85% | 28.86% | 37.00% | 40.49% | 39.78% | 35.44% | 36.47% | 37.16% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 18.97M | 65.88M | 19.78M | -25.20M | 23.67M | -98.55M | -50.00M | -79.88M | -41.00M | -51.13M | 16.76M | 8.32M | -17.53M | 3.92M | 7.10M | 250.79K |
| Income Before Tax | 627.84M | 610.75M | 578.81M | 356.46M | 303.54M | 166.31M | 141.33M | 155.12M | 190.92M | 158.19M | 151.60M | 132.14M | 79.66M | -7.88M | 2.87M | 18.11K |
| Income Before Tax Ratio | 50.50% | 52.67% | 47.39% | 36.12% | 32.40% | 21.88% | 21.32% | 24.42% | 33.33% | 30.07% | 39.84% | 38.92% | 30.46% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 118.35M | 94.55M | 101.08M | 61.26M | 62.66M | 37.62M | 50.00M | 47.33M | 58.40M | 38.54M | 9.63M | 33.93M | 24.77M | -4.11M | -7.47M | -18.11K |
| Net Income | 501.07M | 508.25M | 470.72M | 291.12M | 237.10M | 126.19M | 90.97M | 107.29M | 131.90M | 112.45M | 131.98M | 91.70M | 49.18M | -7.88M | 2.87M | 18.11K |
| Net Income Ratio | 40.30% | 43.83% | 38.54% | 29.50% | 25.31% | 16.60% | 13.72% | 16.89% | 23.03% | 21.37% | 34.69% | 27.01% | 18.80% | 0.00% | 0.00% | 0.00% |
| EPS | 4.12 | 4.18 | 3.87 | 2.40 | 1.99 | 1.59 | 1.25 | 1.36 | 1.60 | 1.49 | 1.79 | 1.31 | 0.69 | -1.13 | 0.41 | 0.01 |
| EPS Diluted | 4.12 | 4.18 | 3.87 | 2.40 | 1.99 | 1.59 | 1.25 | 1.36 | 1.60 | 1.49 | 1.79 | 1.31 | 0.66 | -1.13 | 0.41 | 0.01 |
| Weighted Avg Shares Out | 121.55M | 121.55M | 121.55M | 121.30M | 119.14M | 79.36M | 72.78M | 78.89M | 82.44M | 75.47M | 73.73M | 70.00M | 71.27M | 7.00M | 7.00M | 1.49M |
| Weighted Avg Shares Out (Dil) | 121.55M | 121.55M | 121.55M | 121.30M | 119.14M | 79.36M | 72.78M | 78.89M | 82.44M | 75.47M | 73.73M | 70.00M | 74.51M | 7.00M | 7.00M | 1.49M |
76+ Women-Owned Small Businesses To Support From A Distance
Shop these women-owned small business from afar. They could use a boost right about now.
Leisure Acquisition (NASDAQ:GPAQ) & Global Cord Blood (NASDAQ:CO) Head to Head Contrast
Leisure Acquisition (NASDAQ:GPAQ) and Global Cord Blood (NYSE:CO) are both small-cap unclassified companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and...
Nioh 2 Guide: Tips to Help You Survive the Game Longer; Plus Learn How to Play Co-Op!
Plus, learn how to play co-op!
Global Cord Blood Corporation (CO) Q3 2020 Earnings Call Transcript
CO earnings call for the period ending December 31, 2019.
Sad News for Grand Theft Auto IV Fans as GTA Co-Creator Leaves Rockstar Games: Could GTA 6 Happen without Him?
Rockstar Games will be experiencing the departure of Dan Houser from their company, and as this happens, Grand Theft Auto IV fans are uneasy regarding the issue about whether or not there will be a new GTA 6.
Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2020
Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first...
Afternoon Market Stats In 5 Minutes
Movers Indices • S&P 500 ETF (NYSE:SPY) fell 5.48% to $272.60.• Nasdaq ETF (NASDAQ:QQQ) decreased 4.90% to $194.10.• Dow Jones Industrial Average ETF (NYSE:DIA) fell 6.09% to $235.11.• FTSE/Xinhua China 25 ETF (NYSE:FXI) decreased 3.34% to $38.82.• FTSE Europe ETF...
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced...
Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2020 Financial Results
Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release unaudited financial results for the third quarter...
Critical Survey: Diamond Eagle Acquisition (NYSE:VRT) & Global Cord Blood (NYSE:CO)
Diamond Eagle Acquisition (NYSE:VRT) and Global Cord Blood (NYSE:CO) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst...
Source: https://incomestatements.info
Category: Stock Reports